Special Design for Camptothecin II - Vildagliptin CAS 274901-16-5 Type 2 Diabetes Mellitus (T2DM) API High Purity – Ruifu
Special Design for Camptothecin II -Vildagliptin CAS 274901-16-5 Type 2 Diabetes Mellitus (T2DM) API High Purity– RuifuDetail:
Manufacturer with High Purity and Competitive Price
Supply Vildagliptin and Related Intermediates:
Vildagliptin CAS: 274901-16-5
3-Amino-1-hydroxyadamantane CAS: 702-82-9
L-Prolinamide CAS: 7531-52-4
Boc-L-Proline CAS: 15761-39-4
(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile CAS: 207557-35-5
| Chemical Name | Vildagliptin |
| Synonyms | LAF-237 |
| CAS Number | 274901-16-5 |
| CAT Number | RF-API30 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C17H25N3O2 |
| Molecular Weight | 303.4 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Off-White to White Crystalline Powder |
| Identification | HPLC: Similar to working standard |
| Specific Optical Rotation | -82.0° to -92.0° |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Vildagliptin (CAS: 274901-16-5) with high quality.
Vildagliptin (also known as LAF237 and Zomelis) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus. Novartis has since withdrawn its intent to submit vildagliptin to the FDA, as of July 2008. T it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.
Product detail pictures:
Related Product Guide:
In the past few years, our business absorbed and digested advanced technologies both equally at home and abroad. In the meantime, our company staffs a group of experts devoted to your advancement ofSpecial Design for Camptothecin II -Vildagliptin CAS 274901-16-5 Type 2 Diabetes Mellitus (T2DM) API High Purity– Ruifu, The product will supply to all over the world, such as: Guinea, United Arab emirates, Singapore, Based on our automatic production line, steady material purchase channel and quick subcontract systems have been built in mainland China to meet customer's wider and higher requirement in recent years. We have been looking forward to cooperating with more clients worldwide for common development and mutual benefit!Your trust and approval are the best reward for our efforts. Keeping honest, innovative and efficient, we sincerely expect that we can be business partners to create our brilliant future!
